{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:47:56Z","timestamp":1790315276581,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00777"],"award-info":[{"award-number":["PI20\/00777"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00977"],"award-info":[{"award-number":["PI16\/00977"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Continuous treatment with azithromycin may lead to fewer acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but little is known of its impact on systemic and functional outcomes in real-life settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicenter prospective observational study of patients with severe COPD who started treatment with azithromycin. Tests were compared at baseline and after 3 and 12\u2009months of treatment. These included lung function tests, a 6-min walking test (6MWT), and enzyme-linked immunosorbent assays of serum and sputum markers, such as interleukins (IL-6, IL-8, IL-13, IL-5), tumor necrosis factor receptor 2 (TNFR2), and inflammatory markers. Incidence rate ratios (IRR) and their 95% confidence intervals (95% CI) are reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 478 eligible patients, the 42 who started azithromycin experienced reductions in AECOPDs (IRR, 0.34; 95% CI, 0.26\u20130.45) and hospitalizations (IRR, 0.39; 95% CI, 0.28\u20130.49). Treatment was also associated with significant improvement in the partial arterial pressure of oxygen (9.2\u2009mmHg, 95% CI 1.4\u201316.9) at 12\u2009months. While TNFR2 was reduced significantly in both serum and sputum samples, IL-13 and IL-6 were only significantly reduced in serum samples. Moreover, an elevated serum and sputum IL-8 level significantly predicted good clinical response to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Continuous azithromycin treatment in a cohort of patients with severe COPD and frequent exacerbations can significantly reduce the number and severity of exacerbations and improve gas exchange. Treatment changes the pattern of microorganism isolates and decreases the inflammatory response. Of note, IL-8 may have utility as a predictor of clinical response to azithromycin treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1229463","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T16:02:44Z","timestamp":1690214564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations"],"prefix":"10.3389","volume":"10","author":[{"given":"Ester","family":"Cuevas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Mont\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carrera-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Garc\u00eda-Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salud","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","article-title":"An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal","volume":"204","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1378\/chest.12-1801","article-title":"Preventing acute exacerbations and hospital admissions in COPD","volume":"143","author":"Marchetti","year":"2013","journal-title":"Chest"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e0121257","DOI":"10.1371\/journal.pone.0121257","article-title":"Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/nejmoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1159\/000517781","article-title":"Efficacy of low-dose versus high-dose continuous cyclic azithromycin therapy for preventing acute exacerbations of COPD","volume":"100","author":"Pomares","year":"2021","journal-title":"Respiration"},{"key":"ref8","volume-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","year":"2020"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/RMED.2000.0786","article-title":"Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London chest activity of daily living scale (LCADL)","volume":"94","author":"Garrod","year":"2000","journal-title":"Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/J.JINF.2013.09.003","article-title":"Infectious etiology of acute exacerbations in severe COPD patients","volume":"67","author":"Domenech","year":"2013","journal-title":"J Infect"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1164\/rccm.200402-200OC","article-title":"Azithromycin blocks neutrophil recruitment in pseudomonas endobronchial infection","volume":"170","author":"Tsai","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2249.2007.03299.x","article-title":"Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells","volume":"147","author":"Sugiyama","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1378\/chest.10-0196","article-title":"Chronic macrolide therapy in inflammatory airways diseases","volume":"138","author":"Friedlander","year":"2010","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/copd.s681","article-title":"Role of macrolide therapy in chronic obstructive pulmonary disease","volume":"3","author":"Martinez","year":"2008","journal-title":"Int J COPD"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0014-2999(01)01321-8","article-title":"Anti-inflammatory effects of macrolide antibiotics","volume":"429","author":"Uli","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"ref17","first-page":"169","article-title":"Macrolide antibiotics as biological response modifiers","volume":"1","author":"Rubin","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"030006052093210","DOI":"10.1177\/0300060520932104","article-title":"Mechanism of azithromycin in airway diseases","volume":"48","author":"Yang","year":"2020","journal-title":"J Int Med Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1164\/ajrccm.156.1.9612065","article-title":"Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells","volume":"156","author":"Takizawa","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/J.PUPT.2016.05.005","article-title":"Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells","volume":"39","author":"Mertens","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/J.1574-6968.2008.01145.X","article-title":"Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes","volume":"282","author":"Roberts","year":"2008","journal-title":"FEMS Microbiol Lett"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1183\/09031936.00208011","article-title":"Macrolide effects on the prevention of COPD exacerbations","volume":"40","author":"Yamaya","year":"2012","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0386022","DOI":"10.1128\/SPECTRUM.03860-22","article-title":"Genetic adaptation and acquisition of macrolide resistance in haemophilus spp. during persistent respiratory tract colonization in chronic obstructive pulmonary disease (COPD) patients receiving long-term azithromycin treatment","volume":"11","author":"Carrera-Salinas","year":"2023","journal-title":"Microbiol Spectr"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1229463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T16:03:03Z","timestamp":1690214583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1229463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":24,"alternative-id":["10.3389\/fmed.2023.1229463"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1229463","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"article-number":"1229463"}}